Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Trial Profile

A Phase 3 Randomized, Placebo-Controlled, Double-Masked, Multicenter, Safety and Efficacy Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease

Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2019

At a glance

  • Drugs Brimonidine (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Ocugen
  • Most Recent Events

    • 21 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
    • 02 Jul 2018 According to the Ocugen media release, the U.S. Food and Drug Administration (FDA) has accepted Ocugens New Investigational New Drug (IND) application.
    • 02 Jul 2018 According to the Ocugen media release, this trial is expected top line results in the second half of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top